BeStock  
Stocks › Biotechnology › ZYME

Zymeworks ZYME

US equityMarket cap rank #2745Biotechnology
$26.14 −$0.72 (-2.68%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $26.14 0.00%
Open$26.30
Prev close$26.86
Day range$26.09 – $27.57
Volume738.8K
Market cap$1.81B
P/E (TTM)49.3
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$256.46M+828.7% YoY
Operating profit$177.63M+905.1% YoY
Net profit$173.70M+986.1% YoY
Diluted EPS$2.28+976.9% YoY
Free cash flow-$24.11M+24.2% YoY
Operating cash flow-$24.04M

Revenue, last 8 quarters

$31.0MDec '24$27.1MMar '25$48.7MJun '25$27.6MSep '25$2.5MDec '25$2.4MMar '26$4.6MJun '26$256.5MSep '26

Net profit, last 8 quarters

$-23.5MDec '24$-22.6MMar '25$2.3MJun '25$-19.6MSep '25$-41.2MDec '25$-44.2MMar '26$-45.0MJun '26$173.7MSep '26

Diluted EPS by quarter

-0.31Dec '24-0.30Mar '250.03Jun '25-0.26Sep '25-0.55Dec '25-0.59Mar '26-0.62Jun '262.28Sep '26

Free cash flow by quarter

$-41.8MDec '24$-3.7MMar '25$11.2MJun '25$-31.8MSep '25$-11.0MDec '25$-45.9MMar '26$-31.9MJun '26$-24.1MSep '26

Annual revenue

$39.0MFY20$26.7MFY21$412.5MFY22$76.0MFY23$76.3MFY24$106.0MFY25

Profitability & balance sheet

Operating margin16.6%
Net margin16.3%
Return on equity15.0%
Return on assets5.5%
Return on invested capital11.2%
Current ratio3.30
Liabilities / assets78.0%
Cash & investments$100.46M
Total debt$40.69M
Net cash (debt)$59.77M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $256.46M $4.59M $2.41M $105.97M $2.52M
Total Operating Revenue $256.46M $4.59M $2.41M $105.97M $2.52M
Operating Expense $78.83M $46.74M $49.56M $198.50M $46.64M
Selling and Admin Expenses $42.70M $19.30M $15.10M $61.50M $15.40M
-General & Admin Expense $42.70M $19.30M $15.10M $61.50M $15.40M
Research & Development $36.13M $27.44M $34.46M $137.00M $31.24M
Operating Profit $177.63M -$42.15M -$47.15M -$92.54M -$44.12M
Net Non-Operating Interest Income (Expense) -$4.21M -$3.31M $645,000.00 $13.35M $2.98M
Non-Operating Interest Income $2.47M $3.29M $2.71M $13.35M $2.98M
Non-Operating Interest Expense $6.69M $6.60M $2.07M – –
Other Income (Expense) -$138,000.00 $196,000.00 $120,000.00 -$559,000.00 -$302,000.00
Other Non-Operating Income (Expenses) -$138,000.00 $196,000.00 $120,000.00 $51,000.00 $308,000.00
Pretax Profit $173.25M -$45.29M -$46.35M -$79.75M -$41.48M
Tax -$452,000.00 -$273,000.00 -$2.19M $1.38M -$270,000.00
Net Profit $173.70M -$45.02M -$44.16M -$81.13M -$41.21M
Profit from Continuing Operations $173.70M -$45.02M -$44.16M -$81.13M -$41.21M
Net Income to Parent Company $173.70M -$45.02M -$44.16M -$81.13M -$41.21M
Net Income to Common Stockholders $173.70M -$45.02M -$44.16M -$81.13M -$41.21M
Basic EPS $2.43 -$0.62 -$0.59 -$1.08 -$0.55
Diluted EPS $2.28 -$0.62 -$0.59 -$1.08 -$0.55
Gain on Sale of Security – – – -$610,000.00 -$284,000.00
Special Income (Charges) – – – $0.00 $0.00
-Less:Impairment of Capital Assets – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.18B $396.96M $478.22M $346.53M $346.53M
Total Current Assets $532.40M $298.39M $385.68M $248.77M $248.77M
Cash and Cash Equivalents & Short-Term Investments $100.46M $270.70M $364.73M $228.80M $228.80M
-Cash and Cash Equivalents $100.46M $179.41M $244.28M $41.16M $41.16M
-Short Term Investments $0.00 $91.29M $120.45M $187.64M $187.64M
Receivables $413.86M $5.93M $4.67M $4.64M $4.64M
-Accounts Receivable $413.86M $5.93M $4.67M $4.64M $4.64M
Other Current Assets $18.07M $21.76M $16.28M $15.33M $15.33M
Total Non-Current Assets $644.02M $98.58M $92.54M $97.76M $97.76M
Net PPE $63.50M $27.15M $28.87M $31.23M $31.23M
-Gross PPE $63.50M $27.15M $28.87M $52.10M $52.10M
Investments and Advances $0.00 $51.78M $39.12M $41.79M $41.79M
Goodwill and Other Intangible Assets $547.43M $13.01M $13.19M $13.37M $13.37M
-Goodwill $116.40M $12.02M $12.02M $12.02M $12.02M
-Other Intangible Assets $431.03M $998,000.00 $1.17M $1.35M $1.35M
Non-Current Deferred Assets $5.84M $4.35M $4.71M $4.71M $4.71M
Other Non-Current Assets $27.24M $2.28M $6.65M $6.67M $6.67M
Total Liabilities $918.16M $316.60M $314.63M $78.03M $78.03M
Total Current Liabilities $161.46M $47.24M $35.65M $42.32M $42.32M
Payables $132.37M $27.50M $30.29M $4.91M $4.91M
-Accounts Payable $131.86M $27.46M $30.23M $4.40M $4.40M
-Total Tax Payable $505,000.00 $45,000.00 $66,000.00 $508,000.00 $508,000.00
Short-Term Debt and Capital Lease Obligation $12.44M $3.30M $3.28M $3.47M $3.47M
-Current Capital Lease Obligation $12.44M $3.30M $3.28M $3.47M $3.47M
Current Deferred Liabilities $16.66M $16.44M $2.08M $2.42M $2.42M
Total Non-Current Liabilities $756.70M $269.35M $278.98M $35.71M $35.71M
Long Term Accounts Payable and Other Payables $91.56M – – – –
Long Term Debt and Capital Lease Obligation $40.69M $12.70M $13.76M $14.80M $14.80M
-Long Term Capital Lease Obligation $40.69M $12.70M $13.76M $14.80M $14.80M
Non-Current Deferred Liabilities $26.77M $3.74M $18.43M $20.63M $20.63M
Other Non-Current Liabilities $597.67M $252.91M $246.78M $278,000.00 $278,000.00
Total Equity $258.25M $80.37M $163.59M $268.50M $268.50M
Stockholders' Equity $258.25M $80.37M $163.59M $268.50M $268.50M
Capital Stock $1.15B $1.14B $1.14B $1.11B $1.11B
-Common Stock $1.15B $1.14B $1.14B $1.11B $1.11B
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $127.22M $116.45M $107.53M $114.63M $114.63M
Retained Earnings -$1.01B -$1.17B -$1.07B -$953.16M -$953.16M
Gains/Losses Not Affecting Retained Earnings -$6.66M -$6.69M -$6.57M -$6.08M -$6.08M
-Available for Sale Securities – $51.78M $39.12M – –
-Accumulated Depreciation – – – -$20.88M -$20.88M
Current Accrued Expenses – – – $21.85M $21.85M
Other Current Liabilities – – – $844,000.00 $844,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$24.04M -$31.95M -$45.72M -$33.01M -$10.26M
Net cash flow from continuing operations -$24.04M -$31.95M -$45.72M -$33.01M -$10.26M
Net Income from Continuing Operations $173.70M -$45.02M -$44.16M -$81.13M -$41.21M
Gain/Loss from Continuing Operations $78,000.00 -$301,000.00 -$331,000.00 $532,000.00 $305,000.00
Depreciation & Depletion & Amortization $2.54M $1.95M $2.85M $11.11M $2.01M
Deferred Tax -$1.57M $265,000.00 -$2.20M $945,000.00 $1.41M
Other Non-Cash Items $6.16M $6.13M $2.07M – –
Change in Working Capital -$228.02M -$6.31M -$10.87M $7.50M $18.38M
-Change in Receivables -$290.91M -$1.26M -$36,000.00 $51.20M $24.71M
-Change in Prepaid Assets $6.20M -$383,000.00 -$1.73M $6.51M -$5.12M
-Change in Payables and Accrued Expense $57.28M -$3.64M -$7.77M -$23.69M $402,000.00
-Change in Other Current Liabilities -$821,000.00 -$783,000.00 -$1.01M -$3.34M -$838,000.00
-Change In Other Working Capital $223,000.00 -$248,000.00 -$340,000.00 -$23.17M -$779,000.00
Net cash flow from investing -$389.77M $17.07M $69.96M $26.66M $5.37M
Net Cash Flow from Continuing Investing Activities -$389.77M $17.07M $69.96M $26.66M $5.37M
Net PPE Purchase and Sale -$73,000.00 $0.00 -$216,000.00 -$1.52M -$581,000.00
Net Intangibles Purchase and Sale $0.00 $0.00 $0.00 -$831,000.00 -$139,000.00
Net Investment Purchase and Sale $142.32M $17.07M $70.18M $29.02M $6.09M
Financing Cash Flow $334.85M -$50.02M $178.79M -$18.56M -$18.74M
Net Cash Flow from Continuing Financing Activities $334.85M -$50.02M $178.79M -$18.56M -$18.74M
Net Common Stock Issuance -$261.99M -$51.95M $173.85M -$36.71M -$25.48M
Proceeds from Stock Option Exercised $2.88M $2.89M $9.32M $18.33M $6.83M
Net Other Financing Charges $593.96M -$958,000.00 -$4.39M -$181,000.00 -$88,000.00
Ending Cash Balance $100.46M $179.41M $244.28M $41.16M $41.16M
Net Change in Cash -$78.96M -$64.89M $203.03M -$24.90M -$23.63M
Beginning Cash Balance $179.41M $244.28M $41.16M $66.10M $64.83M
Effect of Exchange Rate Changes $11,000.00 $24,000.00 $98,000.00 -$45,000.00 -$44,000.00
Free Cash Flow -$24.11M -$31.95M -$45.93M -$35.36M -$10.98M

Discussion

No comments yet — be the first to weigh in on ZYME.

Sign in to join the discussion.

Scroll to Top